Exicure, Inc. (XCUR)
| Market Cap | 7.33M -81.2% |
| Revenue (ttm) | n/a |
| Net Income | -8.28M |
| EPS | -1.30 |
| Shares Out | 6.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 151,958 |
| Open | 1.320 |
| Previous Close | 1.300 |
| Day's Range | 1.050 - 1.320 |
| 52-Week Range | 1.050 - 9.480 |
| Beta | 3.66 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About XCUR
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Financial Performance
Financial StatementsNews
Exicure to settle GPCR Therapeutics milestone payment through equity issuance
Exicure (XCUR) announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics during August in settlement of a $1M clinical milestone payment obligation under the…
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therap...
Exicure Announces Board and Committee Changes
WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions a...
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department of Th...
Exicure receives noncompliance notification from Nasdaq
Exicure (XCUR) announced that it received a notification letter from Nasdaq indicating that the company was not in compliance with Nasdaq Listing Rule 5250 due to the delayed filing of…
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
Exicure announced receipt of a Nasdaq notice related to the delayed filing of its Form 10-Q and confirmed that the Form 10-Q was filed on May 29, 2026.
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based bi...
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the follo...
Exicure, Inc. Reports Full Year 2025 Financial Results
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025.
Exicure announces publication of results from Phase 2 study of burixafor
Exicure (XCUR) announced the publication of results from a prior Phase 2 clinical study evaluating burixafor, a highly selective CXCR4 inhibitor, in the journal Annals of Hematology. The manuscript, t...
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant ...
Exicure to present data from burixafor Phase 2 trial at 2026 Tandem Meetings
Exicure (XCUR) announced that it will present a poster at the upcoming 2026 Tandem Meetings Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy...
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it w...
Exicure presents topline data from burixafor combination trial
Exicure (XCUR) announced results from its completed Phase 2 trial evaluating burixafor in combination with propranolol and granulocyte colony-stimulating factor for the mobilization of hematopoietic p...
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive ...
Exicure Inc trading halted, volatility trading pause
10:56 EST Exicure (XCUR) Inc trading halted, volatility trading pause
Exicure, Inc. Reports Third Quarter 2025 Financial Results
REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025.
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that resu...
Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Exicure, Inc. (NASDAQ: XCUR) breached their fiduciary duties to sha...
Exicure appoints Josephine Cardarelli as president, CSO
Following its acquisition of GPCR Therapeutics USA earlier this year, Exicure (XCUR) has been advancing the Phase 2 trial with dedicated internal drug development experts. These scientific leaders bri...
Exicure announces near-term strategic priorities
Exicure’s (XCUR) ongoing Phase 2 study is a randomized, open-label, multicenter trial evaluating burixafor, a small molecule CXCR4 antagonist, in autologous stem cell transplant for multiple myeloma. ...
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Developm...
Exicure, Inc. Reports Second Quarter 2025 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results.
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements.